Long-term outcomes of anterior chest wall arteriovenous graft with polyurethane

J Vasc Access. 2022 Nov;23(6):930-935. doi: 10.1177/11297298211012205. Epub 2021 May 17.


Background: Anterior chest wall arteriovenous graft (ACWAVG) is one option for haemodialysis patients when vessels of the upper extremities become exhausted. We report here the long-term outcomes of ACWAVG with polyurethane.

Methods: From April 2005 to October 2015, nine ACWAVGs with polyurethane grafts were created. We observed patients until April 2019 and evaluated graft patency, interval from operation to first cannulation, and numbers of interventions and complications.

Results: Primary patency rate and secondary patency rate of 6, 12 and 24 months were 55.3%, 33.3%, 33.3% and 77.8%, 55.6%, 55.6% respectively. Mean interval from operation to first cannulation was 3 days. Infection rate and kinking formation rate were slightly higher than previous reports of ACWAVGs with expanded polytetrafluoroethylene (ePTFE). However, one patient was able to keep using a single graft for 166 months with multiple interventions.

Conclusions: Slight disadvantage are seen with patency rate and complication rate in polyurethane ACWAVG compare to ePTFE. However, when early cannulation is required, polyurethane is worth to consider for creating ACWAVG.

Keywords: Anterior chest wall arteriovenous graft; haemodialysis; polyurethane.

MeSH terms

  • Arteriovenous Shunt, Surgical* / adverse effects
  • Blood Vessel Prosthesis / adverse effects
  • Blood Vessel Prosthesis Implantation* / adverse effects
  • Graft Occlusion, Vascular / diagnostic imaging
  • Graft Occlusion, Vascular / etiology
  • Humans
  • Polytetrafluoroethylene
  • Polyurethanes
  • Renal Dialysis / adverse effects
  • Thoracic Wall*
  • Vascular Patency


  • Polyurethanes
  • Polytetrafluoroethylene